<DOC>
	<DOCNO>NCT01893385</DOCNO>
	<brief_summary>The main objective ass variation plasma level cathelicidin influenza vaccination . All bibliographic data suggest supplementation vitamin D elderly often deficient vitamin may double interest : - By induction cathelicidin , assist anti-infective response particular influenza virus - The normalization vitamin D status , promote return appropriate immune response limit excess inflammation improve capacity respond . The entire project collect new information merit use vitamin D aging . A good knowledge mechanism involve impact age necessary prerequisite definition new strategy use drug elderly particularly fragile order improve autonomy . This definition seem sociological interest obvious economic knowing current age population impact future health system .</brief_summary>
	<brief_title>Vitamin D Supplementation Immune Response</brief_title>
	<detailed_description>CONDUCT OF THE STUDY : Visit 1 : selection subject ( CPC / CIC-Inserm CIC501 ) - Medical Examination , clinical examination , explanation protocol collection write consent , - Collection anthropometric data measure size declarative weight form examination , measurement current weight , BMI , waist circumference measurement . - Food Survey . - Fasting blood sampling : dosing vitamin D , cathelicidin , exploration immunocompetent cell , calcium , phosphorus , urea creatinine . Visit 2 : randomization ( CPC / CIC-Inserm CIC501 ) - Fasting blood sampling : dosing vitamin D , cathelicidin , serum calcium , phosphorus , urea creatinine . - Exploration immune cell patient deficient vitamin D ( molecular cellular analyzes ) . Start vitamin D supplementation placebo - Subjects vitamin D level &lt; 30ng/mL randomize two group : - Arm receiving vitamin D ( BS ) . - Arm receiving placebo ( BC ) . - It give patient 4 bulbs product ( vitamin D placebo ) supplementation 2 month ( 1 / 15 day ) . Call subject 4 week vitamin supplementation / placebo assess clinical safety product , well compliance instruction supplementation . Visit 3 : After seven week vitamin supplementation / placebo ( CPC / CIC-Inserm CIC501 ) - Fasting blood assay vitamin D calcium collection . - urinary dosage calcium . Visit 4 : Month 2 ( CPC / CIC-Inserm CIC501 ) - Validation laboratory measurement make independent medical M2 protocol . - Delivery product test third month vitamin supplementation / placebo . For placebo group give two bulbs third month placebo placebo supplementation . For VitD group : dose adjustment accord follow scheme : - If [ 25 ( OH ) D ] &gt; 75 ng / ml / calcium level &gt; 106 mg / ml / calcium excretion &gt; 300 mg / l : presentation two bulb placebo . - If [ 25 ( OH ) D ] &lt; 75 ng / ml serum calcium &lt; 106 mg / ml calcium excretion &lt; 300 mg / l : presentation two ampoule Vitamin D. Visit 5 - Month 3 vaccination INTANZA 15 ® ( 3 month start supplementation ) - Recovery box empty ampoule vitamin D. - Evaluation clinical safety vitamin D. - Collection anthropometric data : measurement current weight BMI , - Fasting blood sampling : dosing vitamin D , cathelicidin , exploration immunocompetent cell , calcium , phosphorus , urea creatinine . - Influenza serology , Visit 6 - Month 4 : end study - Clinical examination assessment tolerability vaccination delivery form reporting due immunization infectious complication side effect accord criterion toxicity CTCNCI Bethesda , - Collection anthropometric data : measurement current weight , calculate weight change , - Fasting blood sampling : dosing vitamin D , cathelicidin , exploration immunocompetent cell , calcium , phosphorus , urea creatinine . - Measurement seroconversion , seroprotection , MGT antibodies follow vaccination . End study Removal anonymity physician investigator propose vitamin D subject receive placebo .</detailed_description>
	<mesh_term>Avitaminosis</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>Aged 65 subject , Subjects vitamin D level 30 ng / ml , Acceptance vitamin D ( 100 000 IU UVEDOSE ® ) Acceptance influenza vaccination INTANZA15 ® Affiliation social security scheme The subject agree change eat habit Liver disease : cirrhosis , chronic hepatitis . Renal impairment whatever degree Hypercalcemia ( serum calcium &gt; 2.6 mol / l ) Hypoor hyperparathyroidism history , history renal colic . Disease / acute infection , moderate severe ( discretion investigator ) day vaccination febrile illness ( temperature ≥ 38 ° C ) . The subject include study condition cure fever go ) . Longterm treatment bisphosphonates , corticosteroid , antiinflammatory , anticonvulsant , antiepileptic , fibrates . Known hypersensitivity vitamin D Prior supplementation ( last year ) supplementation vitamin D Participation time inclusion trial , plan participation period trial , another trial vaccine , drug , medical device . Vaccination 4 week prior vaccination immunization test set three week vaccination test . Transfusion immunoglobulin , blood blood product last 3 month Congenital acquire , know suspected immunodeficiency , immunosuppressive therapy last 6 month , cancer chemotherapy radiotherapy ; steroid longterm systemic ( prednisone equivalent two consecutive week Previous 3 month ) . Systemic Hypersensitivity component vaccine ( ovalbumin , chicken protein , neomycin , formaldehyde , octoxinol 9 ) , history reaction influenza vaccine vaccine contain one substance vaccine trial , involve lifethreatening . Deprivation liberty administrative order issue court , subject emergency medical involuntary hospitalization . Topic enjoy measure legal protection ( guardianship , guardianship ... ) .</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>vitamin D</keyword>
	<keyword>supplementation</keyword>
	<keyword>immunocompetente cell , immune system</keyword>
	<keyword>influenza vaccine</keyword>
	<keyword>elderly</keyword>
</DOC>